학술논문
TEC化疗方案联合保乳术在Ⅱ、Ⅲ期乳腺癌患者治疗中的可行性 / Feasibility of TEC Chemotherapy Combined with Breast-conserving Surgery in the Treatment of Patients with Stage Ⅱ and Ⅲ Breast Cancer
Document Type
Academic Journal
Author
Source
中国医学创新 / Medical Innovation of China. 21(2):40-44
Subject
Language
Chinese
ISSN
1674-4985
Abstract
目的:探讨TEC化疗方案联合保乳术在Ⅱ、Ⅲ期乳腺癌患者治疗中的可行性及对生存质量的影响.方法:选取2018年2月—2020年2月济宁市第三人民医院收治的Ⅱ、Ⅲ期乳腺癌患者172例,依据随机数字表法分为对照组(86 例,常规改良根治术)、观察组(86 例,TEC化疗方案联合保乳术治疗).观察组治疗 3 个月后对两组进行随访.比较两组随访期间的治疗效果,治疗前及治疗 3 个月后血清癌胚抗原(CEA)、糖类抗原 125(CA125)、糖类抗原 153(CA153)、糖类抗原 19-9(CA19-9)水平、生存质量评分,随访期间复发率、远处转移率、不良反应总发生率.结果:与治疗前比,治疗 3 个月后两组血清CEA、CA125、CA153、CA19-9 水平均降低,观察组均低于对照组,差异均有统计学意义(P<0.05);与治疗前相比,治疗 3 个月后两组生存质量各项评分均升高,观察组均高于对照组,差异均有统计学意义(P<0.05);与对照组相比,观察组随访期间临床总有效率更高,并发症总发生率更低,差异均有统计学意义(P<0.05);观察组随访期间复发率、远处转移率、不良反应总发生率均低于对照组,但差异均无统计学意义(P>0.05).结论:TEC化疗方案联合保乳术可以抑制Ⅱ、Ⅲ期乳腺癌患者的肿瘤细胞增殖,改善患者生存质量,且并发症发生率较低.
Objective:To investigate the feasibility of TEC chemotherapy combined with breast-conserving surgery in the treatment of patients with stage Ⅱ and Ⅲ breast cancer and its effect on quality of life.Method:A total of 172 patients with stage Ⅱ and Ⅲ breast cancer admitted to Jining Third People's Hospital from February 2018 to February 2020 were selected and divided into the control group(86 cases,conventional modified radical surgery)and the observation group(86 cases,TEC chemotherapy combined with breast-conserving surgery)according to random number table method.The observation group was treated for 3 months,and then the two groups were followed up.The treatment effect during the follow-up period,serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),carbohydrate antigen 19-9(CA19-9),quality of life score before treatment and after 3 months of treatment,recurrence rate,distant metastasis rate and total incidence of adverse reactions during follow-up were compared between the two groups.Result:Compared with before treatment,the levels of serum CEA,CA125,CA153 and CA19-9 in the two groups after 3 months of treatment decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Compared with before treatment,the scores of quality of life in the two groups after 3 months of treatment increased,and those in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Compared with the control group,the total clinical effective rate was higher and the total incidence of complications was lower in the observation group during the follow-up period,the differences were statistically significant(P<0.05).The recurrence rate,distant metastasis rate and the total incidence of adverse reactions in the observation group were lower than those in the control group during the follow-up period,but the differences were not statistically significant(P>0.05).Conclusion:TEC chemotherapy combined with breast-conserving surgery can inhibit the proliferation of tumor cells and improve the quality of life of patients with stage Ⅱ and Ⅲ breast cancer,and the incidence of complications is low.
Objective:To investigate the feasibility of TEC chemotherapy combined with breast-conserving surgery in the treatment of patients with stage Ⅱ and Ⅲ breast cancer and its effect on quality of life.Method:A total of 172 patients with stage Ⅱ and Ⅲ breast cancer admitted to Jining Third People's Hospital from February 2018 to February 2020 were selected and divided into the control group(86 cases,conventional modified radical surgery)and the observation group(86 cases,TEC chemotherapy combined with breast-conserving surgery)according to random number table method.The observation group was treated for 3 months,and then the two groups were followed up.The treatment effect during the follow-up period,serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),carbohydrate antigen 19-9(CA19-9),quality of life score before treatment and after 3 months of treatment,recurrence rate,distant metastasis rate and total incidence of adverse reactions during follow-up were compared between the two groups.Result:Compared with before treatment,the levels of serum CEA,CA125,CA153 and CA19-9 in the two groups after 3 months of treatment decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Compared with before treatment,the scores of quality of life in the two groups after 3 months of treatment increased,and those in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Compared with the control group,the total clinical effective rate was higher and the total incidence of complications was lower in the observation group during the follow-up period,the differences were statistically significant(P<0.05).The recurrence rate,distant metastasis rate and the total incidence of adverse reactions in the observation group were lower than those in the control group during the follow-up period,but the differences were not statistically significant(P>0.05).Conclusion:TEC chemotherapy combined with breast-conserving surgery can inhibit the proliferation of tumor cells and improve the quality of life of patients with stage Ⅱ and Ⅲ breast cancer,and the incidence of complications is low.